How AI could transform cancer treatment and medicine

Moderna and Merck reported positive Phase 3 trial results for an mRNA melanoma vaccine in development, with full data and FDA approval still pending. The trial evaluated the therapy's effectiveness in melanoma patients, though specific efficacy metrics were not disclosed in available reports. Final regulatory review timelines have not been announced.

Next story